Athos Gianella-Borradori

Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial

Anthony Traboulsee, Benjamin Greenberg, Jeffrey L. Bennett et al. · The Lancet Neurology · 2020 · 456 citations · Full text

Satralizumab Monotherapy, Placebo-controlled Phase 3, Ophthalmology +4

Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies

Reuben Benjamin, Charlotte Graham, Deborah Yallop et al. · The Lancet · 2020 · 344 citations · Full text

Hematological Malignancy, Cell Therapy, Transplantation +9

Seliciclib (CYC202, R-Roscovitine) Induces Cell Death in Multiple Myeloma Cells by Inhibition of RNA Polymerase II–Dependent Transcription and Down-regulation of Mcl-1

David E. MacCallum, Jean Melville, Sheelagh Frame et al. · Cancer Research · 2005 · 284 citations · Full text

Apoptosis, Cell Death, Cell Cycle +16

A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days

Charlotte Benson, Jeff White, Johann S. de Bono et al. · British Journal of Cancer · 2006 · 257 citations · Full text

A Phase 1-2 Clinical Trial of Gene Therapy for Recurrent Glioblastoma Multiforme by Tumor Transduction with the Herpes Simplex Thymidine Kinase Gene Followed by Ganciclovir

N. Shand, Friedrich Weber, Luigi Mariani et al. · Human Gene Therapy · 1999 · 253 citations

Immunology, Pathology, High-grade Gliomas +19